Afrezza (insulin human) is the only FDA-approved inhaled insulin — a rapid-acting insulin powder inhaled through a small device at the start of each meal. It offers an injection-free alternative for mealtime insulin coverage in both Type 1 and Type 2 diabetes.
💨 Inhaled — Not Injected: Afrezza is inhaled through a small, discreet inhaler at mealtime. It does not replace basal insulin — patients with Type 1 diabetes still require a long-acting basal insulin injection alongside Afrezza.
How Afrezza Works
Afrezza uses Technosphere technology — insulin is bound to tiny particles that rapidly dissolve when inhaled, delivering insulin directly across the lung surface into the bloodstream. This results in a pharmacokinetic (PK) profile that more closely mimics natural meal-time insulin release than any injectable rapid-acting insulin:
- Onset: ~12–15 minutes (faster than any injectable)
- Peak: ~45–60 minutes
- Duration: ~2–3 hours (shorter than injectable rapid-acting insulins, which last 4–6 hours)
The faster onset and shorter duration mean Afrezza more precisely covers the glucose spike from a meal — and clears the system faster, reducing the risk of late post-meal hypoglycemia.
Who Is Afrezza For?
- Type 1 diabetes: Used as mealtime insulin alongside a long-acting basal insulin. Approved and effective, though carb counting and dose selection require practice with the available cartridge sizes.
- Type 2 diabetes: An excellent option for patients who need mealtime insulin but resist or struggle with injections. Can be added to oral medications or basal insulin.
- Needle phobia: Patients who avoid mealtime injections often accept Afrezza more readily.
- Unpredictable eating: Because it works so fast and clears quickly, Afrezza can be well-suited for patients with irregular meal timing.
Cartridge Sizes & Dosing
Afrezza comes in color-coded cartridges inserted into a small inhaler device:
| Cartridge | Dose | Approximate Equivalent Injectable Dose |
|---|---|---|
| Blue (4 unit) | 4 units inhaled | ~2–3 units subcutaneous rapid-acting |
| Green (8 unit) | 8 units inhaled | ~4–6 units subcutaneous |
| Yellow (12 unit) | 12 units inhaled | ~6–9 units subcutaneous |
Cartridges can be combined for larger doses. Bioavailability is lower than injected insulin — roughly 25–35% of the inhaled dose reaches the bloodstream — which is why inhaled units don't map 1:1 to injected units. Your endocrinologist will guide your starting dose.
Who Cannot Use Afrezza
- Chronic lung disease (absolute contraindication): Afrezza is contraindicated in patients with chronic obstructive pulmonary disease (COPD) or asthma due to risk of acute bronchospasm. A boxed warning applies.
- Active smokers or those who quit smoking less than 6 months ago (altered lung absorption)
- Patients with lung cancer or other active pulmonary conditions
- Children under 18 (not approved)
- Diabetic ketoacidosis (DKA) — requires injectable insulin
A spirometry (lung function) test is required before starting Afrezza and periodically during treatment to monitor for lung function changes.
Side Effects
- Cough: The most common side effect — occurs in ~25–30% of patients. Usually mild, dry, and brief (seconds after inhalation). Many patients habituate over time.
- Hypoglycemia: As with all mealtime insulins — most common with missed or smaller-than-expected meals
- Throat irritation or discomfort
- Decline in FEV1 (lung function): A small, non-progressive decline in FEV1 has been observed in clinical trials. This is why spirometry monitoring is required.
- Weight gain (less than with injectable insulin in some studies)
Practical Advantages
- No needles for mealtime dosing — dramatically improves adherence for needle-averse patients
- Faster onset means you inhale at the start of eating — no need to pre-bolus 15–20 minutes before meals
- Shorter duration reduces "insulin stacking" and late hypoglycemia risk
- Discreet — the inhaler is small and resembles a common asthma device
- Cartridges do not require refrigeration after opening (store at room temp for up to 10 days)
Insurance & Cost
Afrezza is covered by many commercial insurance plans and some Medicare Part D plans, though it often requires prior authorization. The manufacturer (MannKind Corporation) offers a savings program for eligible commercially insured patients. Medicare coverage varies by plan — check your formulary. Our office can assist with prior authorization.
Key Takeaways
- Afrezza is the only inhaled insulin — a needle-free option for mealtime coverage
- Faster onset (~12–15 min) and shorter duration (~2–3 hr) than any injectable rapid-acting insulin
- Contraindicated in COPD and asthma — spirometry required before and during use
- Does not replace basal insulin in Type 1 diabetes
- Cough is common but usually mild and brief
- Excellent option for needle-averse patients or those needing flexible mealtime dosing
Our Team Can Help with Your Medications
All five of our providers prescribe and manage endocrine medications. Book with any member of our team:
Book an Appointment → or call 832-968-7003